SURGICAL INNOVATIONS GROUP PLC

• ⚠

  Confirmation statement overdue

  Due 2026-03-26.

1. SURGICAL INNOVATIONS GROUP PLC 1998-07-07 → present
2. HAEMOCELL PLC 1988-11-16 → 1998-07-07
3. NEWPOLL PUBLIC LIMITED COMPANY 1988-09-20 → 1988-11-16

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Saffery LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors continue to adopt the going concern basis in the preparation of the financial statements. The Directors have considered the period of at least 12 months from the date of approval of the financial statements in making this assessment. The Directors have prepared forecasts for the period to December 2026 based on a full evaluation of the Group's trading activities and costs base, sensitised to reflect a rational judgement of the level of inherent risk. Financial headroom as of 31 December 2024 was £0.9m with the invoice discounting facility remaining largely undrawn. The Board is satisfied that there is headroom including testing any sensitivities under reasonably possible scenarios, and the Directors conclude that it continues to be appropriate to prepare the Annual Report and Accounts on a going concern basis.”

Group structure

1. SURGICAL INNOVATIONS GROUP PLC · parent
   1. Surgical Innovations Limited 1% · Great Britain · Design and manufacture of minimally invasive devices
   2. Haemocell Limited 1% · Great Britain · Design and manufacture of Autologous blood products
   3. Elemental Healthcare Ltd 1% · Great Britain · Distribution of innovative Medical products

Significant events

• “The Company concluded the year with stable revenues, a strengthened operational position, and a range of significant new opportunities. These include the introduction of SI-branded products and the expansion of distribution agreements within the UK.”
• “A project focused on reducing operational overheads was completed in early Q3, with the benefits beginning to be realised in H2 and expected to continue into 2025.”
• “Elemental has secured a new five-year exclusive UK distribution agreement with Microline Surgical Inc.”
• “The Company has also signed new agreements with Cipher Surgical Ltd., Aspen Surgical Inc., and Veol Medical Technologies, broadening its portfolio with an exciting range of medical devices for the UK healthcare market.”
• “A significant restructuring of the business was carried out and finalised by September 2024, which included a reduction in headcount from 105 to 85.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

8

last 12 months

Capital events

0

last 24 months

Officers appointed

3

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -0.6%

  £12,014,000 → £11,945,000

• Cash

  -83.9%

  £1,212,000 → £195,000

• Net assets

  -18.5%

  £10,484,000 → £8,541,000

• Employees

  -12.9%

  101 → 88

• Operating profit

  -32.7%

  -£596,000 → -£791,000

• Profit before tax

  -181.6%

  -£728,000 → -£2,050,000

• Wages

  -12.9%

  £4,230,000 → £3,683,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers